BNGO
Bionano Genomics, Inc.Company Information
- Company Name
- Bionano Genomics, Inc.
- CIK
- CIK0001411690
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BNGO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3826
- SIC Description
- Laboratory Analytical Instruments
- Ticker
- BNGO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-04
- Last sale
- —
- Shares purchased (TTM)
- 8,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 547,581
- Shares outstanding
- 11,546,000
- Ownership
- 4.74%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 3.45%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 4 | 3 | 3 | 3 | 4 | 4 | 9 | 9 | 10 | 16 | 18 | 35 | ||||||
| Available For Sale Securities Debt Securities Current | 6 | 11 | 16 | 19 | 13 | 15 | 0 | 3 | 9 | 13 | 49 | 29 | ||||||
| Accounts Receivable Net Current | 4 | 4 | 5 | 5 | 3 | 3 | 5 | 5 | 6 | 8 | 9 | 9 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 4 | 5 | 5 | 6 | 6 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | 11 | - | - | - | ||||||
| Restricted Investments Current | - | - | 10 | 10 | 11 | 11 | 11 | 11 | 0 | 24 | 35 | - | ||||||
| Restricted Cash And Investments Current | 1 | 10 | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 25 | 39 | 45 | 49 | 43 | 45 | 39 | 47 | 61 | 86 | 140 | 105 | ||||||
| Restricted Cash Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 25 | 25 | 23 | 21 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 6 | ||||||
| Finance Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 3 | 4 | 6 | 7 | 8 | 10 | 11 | 30 | 32 | 34 | 36 | ||||||
| Other Assets Noncurrent | 2 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 6 | 7 | 7 | 10 | ||||||
| Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 48 | 65 | 74 | 79 | 76 | 78 | 77 | 87 | 129 | 158 | 214 | 182 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 9 | 9 | 10 | 10 | 15 | ||||||
| Accrued Liabilities Current | 3 | 4 | 5 | 5 | 3 | 4 | 6 | 6 | 6 | 11 | 8 | 12 | ||||||
| Contract With Customer Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 10 | ||||||
| Liabilities Current | 10 | 21 | 23 | 23 | 24 | 26 | 37 | 33 | 37 | 59 | 100 | 40 | ||||||
| Operating Lease Liability Noncurrent | 2 | 3 | 2 | 3 | 3 | 0 | 0 | 2 | 2 | 3 | 4 | 4 | ||||||
| Finance Lease Liability Noncurrent | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 6 | 10 | 11 | 15 | ||||||
| Liabilities | 16 | 27 | 29 | 29 | 31 | 30 | 41 | 38 | 49 | 75 | 118 | 63 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 767 | 765 | 764 | 761 | 749 | 745 | 729 | 720 | 709 | 695 | 677 | 656 | ||||||
| Retained Earnings Accumulated Deficit | -735 | -728 | -720 | -712 | -703 | -696 | -693 | -673 | -629 | -613 | -581 | -537 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 2 | -0 | -0 | 0 | -0 | ||||||
| Stockholders Equity | 32 | 37 | 44 | 50 | 45 | 48 | 35 | 49 | 80 | 83 | 96 | 119 | ||||||
| Liabilities And Stockholders Equity | 48 | 65 | 74 | 79 | 76 | 78 | 77 | 87 | 129 | 158 | 214 | 182 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 12 | 11 | 11 | 10 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 12 | 11 | 11 | 10 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBionano Genomics, Inc. (BNGO) — SEC Financial Statements & Analysis
Bionano Genomics, Inc. (BNGO) is a laboratory analytical instruments company, incorporated in DE. Bionano Genomics, Inc. trades on Nasdaq as: BNGO. Bionano Genomics, Inc. (BNGO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Bionano Genomics, Inc. carries a market cap of $13.05M, a P/E ratio of -0.41x, a P/B ratio of 0.41x, a P/S ratio of 0.43x, an enterprise value of $12.50M, and an EV/EBITDA multiple of -0.55x. On profitability, it posts a gross margin of 47.51%, an operating margin of -106.67%, a net margin of -106.58%, a Return on Equity (ROE) of -83.56%, a Return on Assets (ROA) of -52.04%, and a Return on Invested Capital (ROIC) of -82.58%. Per share, it reports EPS of $-2.79, diluted EPS of $-2.79, free cash flow per share of $-1.77, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.03% year-over-year, net income growth of -56.73% year-over-year, and EPS growth of -87.10% year-over-year. On the balance sheet, it maintains a current ratio of 2.48x, a quick ratio of 1.99x, working capital of $14.84M, a debt-to-equity ratio of 0.51x, a debt ratio of 0.34, an interest coverage ratio of -35.26x, free cash flow of $-20.48M (TTM), and net debt of $-544.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $13.05M
- P/E TTM
- -0.41x
- EPS TTM
- $-2.79
- P/B TTM
- 0.41x
- ROE TTM
- -83.56%
- ROA TTM
- -52.04%
- Debt To Equity
- 0.51x
- Free Cash Flow TTM
- $-20.48M
- Net Revenue TTM Growth 1Y
- 10.03%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Bionano Genomics, Inc. in?
Bionano Genomics, Inc. (BNGO) operates in the Laboratory Analytical Instruments industry.
What exchange does BNGO trade on?
Bionano Genomics, Inc. (BNGO) trades on the Nasdaq.
Where is Bionano Genomics, Inc. incorporated?
Bionano Genomics, Inc. is incorporated in DE.
When was Bionano Genomics, Inc. (BNGO)'s most recent SEC filing?
Bionano Genomics, Inc. (BNGO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is BNGO's market cap?
Bionano Genomics, Inc. (BNGO) has a market capitalization of $13.05M as of 2026-06-30.
What is BNGO's EPS (earnings per share)?
Bionano Genomics, Inc. (BNGO)'s trailing twelve month EPS is $-2.79 as of 2026-06-30.
What is BNGO's ROE (return on equity)?
Bionano Genomics, Inc. (BNGO)'s trailing twelve month Return on Equity (ROE) is -83.56% as of 2026-06-30.
What is BNGO's ROA (return on assets)?
Bionano Genomics, Inc. (BNGO)'s trailing twelve month Return on Assets (ROA) is -52.04% as of 2026-06-30.
What is BNGO's ROIC (return on invested capital)?
Bionano Genomics, Inc. (BNGO)'s trailing twelve month Return on Invested Capital (ROIC) is -82.58% as of 2026-06-30.
What is BNGO's EV/EBITDA?
Bionano Genomics, Inc. (BNGO)'s trailing twelve month EV/EBITDA is -0.55x as of 2026-06-30.